Real-World Evidence (RWE) Solutions Market Worth $3.13 Billion by 2027- Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

NEXT STORY
New Expanded, Updated Edition of OnePoint Patient Care Clinical Symptom Guide Now Available
PREV STORY
Vector Solutions Adds Silent Panic Alarm Feature to its LiveSafe Tip Reporting and Safety Communications Platform for Schools
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Insights on the Custom Antibody Global Market to 2028 – by Service, Type, Source, and Research Area, End Users and Geography

author_avatar
NASDAQ Market News

Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection

author_avatar
NASDAQ Market News

アイデラ・ファーマシューティカルズ (Idera Pharmaceuticals)、実施中のPD-1治療抵抗性の転移性メラノーマ患者におけるイピリムマブ併用の腫瘍内IMO-2125の第1相試験の用量漸増試験で、有望なデータを報告

－ PD-1治療抵抗性の皮膚メラノーマの3人の患者に奏効し、そのうちの1人では完全奏効 (CR) を実現 － － IMO-2125の臨床開発の優先度が高くなったため、同社はB細胞リンパ腫治療のためのIMO-8400の開発を一時中止 － セッツ州ケンブリッジおよびペンシルベニア州エクストン, Sept. 27, 2016 (GLOBE NEWSWIRE) ...

author_avatar
NASDAQ Market News